Investigators will present detailed findings from a phase 2 study assessing a tambiciclib-based regimen in patients with relapsed/refractory AML at ASH 2026.
News|Videos|December 13, 2016
Treatment Approaches for Therapy-Related AML, MDS Based on Mutation Profiles
Author(s)Michael Heuser, MD
This video examines different mutational profiles of therapy-related myeloid neoplasms and how they can affect approaches to treatment.
Advertisement
In this video, Michael Heuser, MD, of the Hannover Medical School in Germany, discusses different mutational profiles of therapy-related myeloid neoplasms, such as acute myeloid leukemia (AML) and myelodysplastic syndromes, and how these genetic profiles can affect approaches to treatment.
Dr. Heuser spoke at an education session on AML at the 58th Annual Meeting of the American Society of Hematology, held December 3–6 in San Diego, California.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors
2
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
3
Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC
4
European Commission Expands Melflufen Label to Third-Line Multiple Myeloma
5